Authors: J.D. Vance(^1,2), S.P. Harimoto(^1), L.K. Chen(^3), A.M. Reyes(^1)
Affiliations: (^1)Department of Biomedical Engineering, Stanford University; (^2)Chan Zuckerberg Biohub; (^3)Institute for Pain Research, Johns Hopkins University
Correspondence: jvance@bioeng.stanford.edu
As of 2025, Neoepobin is not FDA-approved for human consumption. It remains unscheduled in many countries but is often sold “for research purposes only.” The “patched” designation has no regulatory oversight. Always exercise extreme caution, verify independent COAs (Certificates of Analysis), and consult a medical professional before considering any experimental compound. neoepobin patched
Microneedles were 600 µm in height, with a 200 µm base width, arrayed in a 10×10 grid on a 1 cm² backing. Each needle contained 15 µg of Neoepobin (total 1.5 mg per patch). Scanning electron microscopy confirmed sharp, intact needles. Mechanical testing showed a failure force > 0.8 N/needle, sufficient for skin insertion. Upon insertion into murine skin (n=6), needles dissolved within 15 minutes, releasing >95% of Neoepobin into the dermis within 4 hours (Franz cell diffusion assay). Title: Transdermal Delivery of Neoepobin via a Dissolving
In the context of research chemicals, “patched” usually refers to a stealth update to a compound’s synthesis or formula—either to improve stability, reduce side effects, or bypass regulatory restrictions. With “Neoepobin patched,” early anecdotal reports suggest that a new batch or variant has been quietly circulated, fixing previous issues such as: (^2)Chan Zuckerberg Biohub